Albert Bourla said Pfizer has discussed a fast-pass voucher with the White House during the JPMorgan Healthcare Conference.

Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted ...

The drug giant's experimental lung cancer drug, crizotinib, will be reviewed on a priority basis by U.S. regulators for treatment of patients with a certain form of the disease. The FDA will ...

Pfizer has ceased development of its oral GLP-1 weight loss drug candidate, danuglipron, after a study participant “experienced potential drug-induced liver injury,” the company said April 14. In dose ...

The Food and Drug Administration may revoke authorization for Pfizer’s COVID-19 vaccine for healthy children under age 5, the pharmaceutical company confirmed, which would limit parents' vaccine ...

Pfizer heads into 2026 with a share price still shaped by the boom and bust of COVID products and a shareholder base that increasingly cares more about income than growth. The company's dividend has ...

(Reuters) -Pfizer filed a second lawsuit on Monday accusing Danish drugmaker Novo Nordisk of structuring its $9 billion bid for Metsera to stall the entry of the biotech firm's treatments into the ...